CORALVILLE, Iowa – IDx has raised $33 million to accelerate market adoption of its autonomous artificial intelligence diagnostic system. The system, cleared by the U.S. Food and Drug Administration, does not require a clinician to interpret the image or results. “We expect this investment to accelerate the adoption of IDx-DR, a unique and much-needed solution for the 30 million people with diabetes in the U.S. alone who need to be tested for diabetic retinopathy each year,” said Stefan Abrams, vice chairman at IDx, in a statement. The FDA-cleared IDx-DR system enables health care providers who are not normally involved in eye care to use the AI system to test for diabetic retinopathy, a leading cause of blindness. In June, IDx-DR was initiated into clinical practice at University of Iowa Health Care, marking the first time patients have received a medical diagnosis from an autonomous AI system in the United States, Abrams said. The company is currently working on implementations at several additional health care systems that plan to go live with IDx-DR in 2018. IDx is also developing AI-based diagnostic systems for the detection of macular degeneration, glaucoma, Alzheimer’s disease, cardiovascular disease and stroke risk.
You are here: / / IDx raises $33M for AI diagnostics